We strive to expand the breadth of our pipeline, covering solid tumor diseases areas, through a combination of targeted therapy and with immune-oncology approaches. We believe the potential best-in-class molecules, Gunagratinib (ICP-192), Zurletrectinib (ICP-723), our rapidly maturing early-stage pipeline, including the cornerstone therapy ICP189 and ICP-B05, will enable us to establish a solid footprint in the field of solid tumor treatment.

We have fortified our powerful discovery engine in the global frontier targets for the development of autoimmune therapeutics through B-cell and T-cell pathways for the purpose of providing the first-in-class and/or best-in-class treatments to the massive unmet clinical needs with a promising market potential in global and/or regional markets.

With orelabrutinib serving as our backbone therapy and a key component of our extensive pipeline in hemato-oncology – including tafasitamab, ICP-B02, ICP-490, ICP-248, potential future developments from internal and external sources – our goal is to address various segments, such as non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and leukemia, utilizing both single and combination therapies, with the aim to become a leading player in hemato-oncology both in China and worldwide.